TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Index of microcirculatory resistance (IMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence, progression and/or death from cancer
Endpoint domain: Mortality/survival
Primary endpoint: Total score at Post-treatment of the Client Satisfaction Questionnaire-8 (CSQ-8)- Patient
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total score at Post-treatment of the Client Satisfaction Questionnaire-8 (CSQ-8)- Partner
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acute Cellular Rejection (ACR) grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of naftifine hydrochloride cream
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of HABP/VABP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of decline in SARS-CoV-2 viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Median Values of ERG Scotopic Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Form Health Survey, 12-Item SF-12v2 quality of life scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Multidimensional Assessment of Fatigue (MAF) scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Work Productivity and Activity Impairment Questionnaire (WPAI) scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Functional Outcomes of Bracing Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Spent in Brace
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Brace Compliance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: HIV Care Engagement
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Attitudes Toward People Living With HIV, Blame/Judgement Subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Grade 3 or higher gastrointestinal toxicity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Standardized Mini-mental State Examination (SMMSE)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Montreal cognitive assessment scale (MOCA, Urdu version)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Trail Making Test-A (TMT-A)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Trail Making Test-B (TMT-B)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Verbal fluency test (VFT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: HIV Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of prescriptions for hypnotic medications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Child & Youth Resilience Measure - Revised (CYRM-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Perceived Stress Survey Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Sleep Hygiene utilizing PSQI survey
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: toxicity of intrapleural BG00001
Endpoint domain: Adverse events/effects
Primary endpoint: AUC(0-inf) of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variations in ECG readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of educational intervention on rash management
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Success rate at the end of treatment period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NASH resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Bound area under the plasma concentration-time curve (AUC0-24h) relative to the minimal inhibitory concentration (MIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unbound AUC0-24h/MIC ratio as predictive parameter for efficacy of unbound MFX dose escalated treatment of tuberculosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of patients having adverse effects, including QT interval prolongation, hypersensitive reactions, diarrhoea, vomiting and hepatic or renal injury
Endpoint domain: Adverse events/effects
Primary endpoint: Pulmonary Vascular Hemodynamics (Rest)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulmonary Vascular Hemodynamics (Exercise)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of life with Oxford Hip Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life with EuroQol Questionnaire (EQ-5D)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Conversion ratio of the daily dose of tacrolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of the first tacrolimus trough level (C0) after conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of additional visits considered by the physicians to be due to the conversion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: sensitivity of the prostasome purification methodology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity of the prostasome purification methodology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in family harmony
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Changes in family happiness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in family health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recurrence of acute right heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acute right heart failure-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Compliance with Obstetric and Diabetes Care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of subjects with similar blood chemistry values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Degree of the dual-task interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Who Discontinue Study
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom From MRI-scan Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Percent change in the production rate of VLDL apo B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of infective endocarditis
Endpoint domain: Mortality/survival
Primary endpoint: Change in PHQ-9 Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral Glucose Insulin Sensitivity (OGIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Arrhythmia risk variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Restenosis assessed by IVUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rates of Surgical Site Infections (SSI)
Endpoint domain: Adverse events/effects
Primary endpoint: NK cell activity to predict prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hospitalizations for severe neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: PD parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of ENB003 in combination with pembrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal function measured by GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Blood Oxygenation at the Optic Nerve Head
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Roland Morris Disability Questionnaire (RMDQ-23)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quadruple Visual Analogue Scale (QVAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paediatric Asthma Control Test (P-ACT)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Haemodynamic Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severity of the Pain at Its Worst
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weeks of Abstinence From Cocaine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Opiate Positive Urines at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opiate Positive Urines at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune System Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in Bone Edema/Osteitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Adherence to PrEP medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Classification as responders or non-responders based on ADHD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NGMN plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EE plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Peri-wound Skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Adenoma detection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Root canal working length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improved balance control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduced Fear of falling
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in foot volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of AT13387
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of AT13387
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual ridge resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD Symptom Scale interview (PSS-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Metrnl levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tolerability to oral ursodeoxycholic acid
Endpoint domain: Adverse events/effects
Primary endpoint: TESGO composite outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of Respiratory Failure
Endpoint domain: Mortality/survival
Primary endpoint: Difference in VEGF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cancer progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Patients With Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Load-induced serum Cartilage Oligomeric Matrix Protein concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of participants who receive >75% of scheduled doses
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent of participants experiencing a CTCAE 5.0 grade 3 or higher related to the study drug
Endpoint domain: Adverse events/effects
Primary endpoint: Change in disease activity score 28 (DAS28) ESR score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: venous leg ulcer healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants With Serum Potassium >6.5 mEq/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Participants With Serious Hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Mitral Annular E' Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of PIVCs Sites With at Least One Clinical or Mechanical Complication
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of participants with more than 10% increase of cardiac index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recommended Phase II dose (RPIID)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Positive PSADT Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance to therapy (%)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Persistence of therapy (Yes or No)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Overall adherence to therapy (Yes or No)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: DNA methylation status of adipocytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: failure rate after one year for grafting
Endpoint domain: Mortality/survival
Primary endpoint: Frequency and severity of treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency and severity of serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean expanded disability status scale (EDSS) score at the end of trial participation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients having the mean EDSS score of less than or equal to 3.0 and more than or equal to 3.5 at the end of the trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean frequency of complications recorded after start of betaferon therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of successful Lumbar Fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall Confirmed Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall rate of PrEP engagement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: safety and efficacy of B2036-PEG therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the Last 30-day Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ED Provider to Decision Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-paroxysmal disability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peri-Implant Mucosal Zenith Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: American Orthopedic Foot and Ankle Score (AOFAS) mid foot scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of uncovered strut
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Learning rate difference between win-volatile and loss-volatile blocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventricular arrhythmia in the electrocardiogram (EKG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Advanced conduction abnormalities and significant ST shifts (> 1 mm) in the EKG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Intending to Start Using PrEP Over Time
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Using PrEP Over Time
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Clinical Cure in Each Study Arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Solicited Urogenital Adverse Events (AEs) Following the First Dose of the Study Product
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Serious Adverse Events (SAEs) Considered Product-related
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Symptom Scores of Vaginal Dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Symptom Scores of Dyspareunia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety based on adverse event reporting
Endpoint domain: Adverse events/effects
Primary endpoint: Change in IPSS sum score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quality-of-Life Index (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ease of swallowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: removal of the LMA Supreme Device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: intraoperative episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebral hemodynamic and blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: WOMAC questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Glycosylated Haemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants completing therapy sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prolonged grief symptoms assessed with PG-13 summary score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With Bone Metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Urethral Perfusion index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial onset seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percentage of patients with therapeutic success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Factor V levels at day 3 after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total dose of intraoperative fentanyl boluses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life 4 weeks after palliative surgery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Phenoxymethylpenicillin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative MACE
Endpoint domain: Mortality/survival
Primary endpoint: Rate of T Stage Downstaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Preoperative Gastrointestinal Morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Surgical Site Infection (SSI) reduction
Endpoint domain: Adverse events/effects
Primary endpoint: Knee Outcome Score (KOOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Disabilities of the Arm, Shoulder and Hand (DASH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Peroperative round window exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of people developing symptomatic illness
Endpoint domain: Adverse events/effects
Primary endpoint: Development of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of intracyclic bleeding episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: USADE at 1 month post implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of abnormal fetal heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of days filled for sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep